VEGF 165 (AA 27-191) (Active) Protein

Catalog No. ABIN2018443

Recombinant protein expressed in HEK-293T Cells.

Quick Overview for VEGF 165 (AA 27-191) (Active) Protein (ABIN2018443)

Target: VEGF 165

Protein Type: Recombinant

Biological Activity: Active

Origin: Human

Source: HEK-293T Cells

Purity: > 95 % as analyzed by SDS-PAGE.

Product Details

Protein Characteristics: AA 27-191

Characteristics: ED50 <16 ng/mL, measured in a cell proliferation assay using HUVEC cells.

Endotoxin Level: < 0.2 EU/μg, determined by LAL method.

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Reconstituted in ddH2O or PBS at 100 μg/mL.

Buffer: Lyophilized after extensive dialysis against PBS.

Storage: -80 °C

Storage Comment: Lyophilized recombinant Human Vascular Endothelial Growth Factor 165 (VEGF-165) remains stable up to 6 months at -80°C from date of receipt. Upon reconstitution, Human Vascular Endothelial Growth Factor 165 (VEGF-165) should be stable up to 1 week at 4°C or up to 2 months at -20°C.

Expiry Date: 6 months

Target Details

Target: VEGF 165

Alternative Name: Vascular Endothelial Growth Factor 165 (VEGF165)

Background: Vascular Endothelial Growth Factor is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothelial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intra-ocular neovascular syndromes. VEGF signals through the three receptors, fms-like tyrosine kinase (flt-1), KDR gene product (the mouse homolog of KDR is the flk-1 gene product) and the flt4 gene product.
Synonyms: Vascular Endothelial Growth Factor, VPF, Folliculostellate cell-derived growth factor, Glioma-derived endothelial cell mitogen

Molecular Weight: 20-26 kDa, observed by reducing SDS-PAGE.

NCBI Accession: NP_001165097